MOTHAFFAR RIMAWI to Predictive Value of Tests
This is a "connection" page, showing publications MOTHAFFAR RIMAWI has written about Predictive Value of Tests.
Connection Strength
0.115
-
A composite 18F-FDG PET/CT and HER2 tissue-based biomarker to predict response to neoadjuvant pertuzumab and trastuzumab in HER2-positive breast cancer (TBCRC026). Breast. 2025 Jun; 81:104432.
Score: 0.040
-
Updated Results of TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol. 2021 07 10; 39(20):2247-2256.
Score: 0.031
-
TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. J Clin Oncol. 2019 03 20; 37(9):714-722.
Score: 0.026
-
Predictors of post-mastectomy reconstruction in an underserved population. J Plast Reconstr Aesthet Surg. 2013 Jun; 66(6):763-9.
Score: 0.018